Status:

COMPLETED

Reletex Versus Standard of Care Therapy for Post-Operative Nausea Control in Patients Undergoing Foregut Surgery

Lead Sponsor:

Kyle A Perry

Conditions:

Nausea and Vomiting Post-foregut Surgery

Eligibility:

All Genders

18-85 years

Phase:

NA

Brief Summary

The effect a ReletexTM device has on postoperative nausea and vomiting when used with ondansetron after foregut surgery will be studied. A ReletexTM device is a FDA approved wristwatch-like device tha...

Eligibility Criteria

Inclusion

  • Age 18-85
  • Planned fundoplication
  • Willingness to comply with randomization and follow-up protocol
  • English speaking

Exclusion

  • \< 18 years of age or \> 85
  • Chronic nausea requiring medical treatment
  • Planned concomitant procedures
  • Pacemaker or automatic internal cardiac defibrillator

Key Trial Info

Start Date :

August 1 2011

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

August 1 2012

Estimated Enrollment :

100 Patients enrolled

Trial Details

Trial ID

NCT01510379

Start Date

August 1 2011

End Date

August 1 2012

Last Update

March 5 2014

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

The Ohio State University Medical Center

Columbus, Ohio, United States, 43210

Reletex Versus Standard of Care Therapy for Post-Operative Nausea Control in Patients Undergoing Foregut Surgery | DecenTrialz